Scott M Rocklage has sold APRE and made no open-market buys since May 2020

Scott M. Rocklage, Ph.D., is a corporate insider and biotechnology investor who serves as Director and 10% owner of Aprea Therapeutics, Inc. (APRE).( SEC and insider-trading databases list him under CIK 0001219014 as a reporting person with substantial holdings in Aprea Therapeutics and other life-science companies, reflecting his role as a significant shareholder and board-level insider in the biopharmaceutical sector.( He has been involved in multiple Form 4 filings for Aprea, documenting several insider transactions in the company’s stock.(

Beyond Aprea Therapeutics, Rocklage is an experienced industry figure with broad exposure across biotech and pharma investments, including positions and ownership stakes in companies such as Relypsa, Cidara Therapeutics, and others, often in director or major-investor capacities.( Public company and venture-capital disclosures describe him as Scott M. Rocklage, Ph.D., indicating a doctoral-level scientific or technical background that underpins his career as a healthcare-focused investor and board member.( While detailed educational history is not included in the cited filings, his repeated designation as Ph.D. and his long-standing presence on boards of clinical-stage and commercial biopharmaceutical companies suggest a career centered on life-science innovation, corporate governance, and strategic financing in the biotechnology industry.(

Written by Perplexity from public sources.